Press release content from Globe Newswire. The AP news staff was not involved in its creation.
CRISPR Therapeutics Presents Preclinical Data at AACR 2021 Supporting CD70 Knockout as a Novel .
CRISPR Therapeutics AGApril 10, 2021 GMT
ZUG, Switzerland and CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced preclinical data from the Company’s allogeneic chimeric antigen receptor T cell (CAR-T) program at the American Association for Cancer Research (AACR) Annual Meeting 2021. The data, presented today in an e-poster session entitled,
CD70 knockout: A novel approach to augment CAR-T cell function, found that the generation of CAR-T cells including knockout of the CD70 show improved properties including potency and persistence over CAR T cells where the CD70 gene remains intact.
Search jobs 10-Apr-2021 Freenome Presents Data Revealing Signatures of Immune Checkpoint Inhibitor Treatment Response Found to Be Common Across Kidney, Melanoma, and Lung Cancers
Freenome demonstrates potential for patient stratification and monitoring using its multiomics platform at the American Association for Cancer Research (AACR) Annual Meeting
SOUTH SAN FRANCISCO, Calif. (BUSINESS WIRE) #aacr21 Freenome, a privately held biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection using a routine blood draw, today announced results of an analysis revealing the potential to use its platform for patient stratification and monitoring. Plasma samples from patients with kidney (n=21), melanoma (n=14) or non-small cell lung cancer (n=91) revealed signatures of immune checkpoint inhibition treatment response found to be common across all three cancer types. Whole-genome cell-free DNA (cfDNA)
Date Time
Mutant KRAS and p53 cooperate to drive pancreatic cancer metastasis
Researchers at The University of Texas MD Anderson Cancer Center have discovered that mutant KRAS and p53, the most frequently mutated genes in pancreatic cancer, interact through the CREB1 protein to promote metastasis and tumor growth. Blocking CREB1 in preclinical models reversed these effects and reduced metastases, suggesting an important new therapeutic target for the deadly cancer.
“To our knowledge, this is the first study to show how these two major genetic drivers work together to promote tumor growth and metastasis,” Kim said. “We learned that signaling downstream of mutant KRAS directly promotes mutant p53 activity. This discovery provides not only a new therapeutic target but unveils a vast transcriptional network that is activated downstream of these mutant proteins.”
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
OncXerna Therapeutics Provides New Results from its Xerna™ RNA-based Biomarker Platform at the .
OncXerna Therapeutics, Inc.April 10, 2021 GMT
Xerna™ TME Panel describes the tumor microenvironment based on dominant biology subtypes with prognostic capabilities in colorectal cancer
Data supports the application of Xerna™ TME Panel beyond gastric and ovarian cancers for prospectively-driven trials with OncXerna’s clinical-stage programs
WALTHAM, Mass., April 10, 2021 (GLOBE NEWSWIRE) OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-expression based biomarker platform to predict patient responses to its first-in-class targeted oncology therapies, today presented new results from its Xerna™ TME Panel during Week 1 of the American Association for Cancer Research (AACR) Annual Meeting. In this study, OncXerna demonstrated that the first panel (TME
NuCana plc: NuCana Announces Five Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2021
NUC-3373 Promotes Natural Killer Cell Activation by Colorectal Cancer Cells
NUC-7738 Demonstrates Anti-Cancer Activity, Prolonged Stable Disease and a Favorable Tolerability Profile in Patients with Advanced Solid Tumors
NUC-7738 Generates High and Prolonged Intracellular Levels of the Active Anti-Cancer Metabolite 3 -dATP
Acelarin Induces Persistent DNA Damage in Biliary Tract Cancer Cells
EDINBURGH, United Kingdom, April 10, 2021 (GLOBE NEWSWIRE) NuCana plc (NASDAQ: NCNA) announced the presentation of five posters at the American Association for Cancer Research (AACR) Annual Meeting 2021 being held virtually April 9 to 14, 2021. Data from all three of NuCana s ProTides in clinical development were presented. Summaries of the posters are described below.